Study of Interleukin-13 and Alpha-1-defensin levels in patients with chronic diffuse liver diseases
Pryshchepenko V.A., Yupatov G.I., Okulich V.K.
Vitebsk State Medical University, Vitebsk, Belarus
Objective - To study the levels of IL-13 and DEFA1 in patients with chronic diffuse liver diseasesand evaluate its relationships with clinical and laboratory data.
Materials and methods. The levels of IL-13 and DEFA1 were determined in 25 people diagnosed with Chronic hepatitis and 40 - Liver cirrhosis. The control group included 15 healthy people. The levels of IL-13 and DEFA1 were determined by the Elisa method.
Results and discussion. Patients with chronic hepatitis and cirrhosis have elevated levels of IL-13 compared with healthy individuals (p<0.01). At the same time, there were no significant differences between the groups of chronic hepatitis and cirrhosis. The following relationships have been established between the level of IL-13 and thelevels of leukocytes and lymphocytes in the general blood test, the level of total bilirubin, the de Rytis index and alpha-amylase activity (p<0.05). The level of DEFA1 in patients with chronic hepatitis and cirrhosis was significantly higher than in the control group (p<0.001). The level of DEFA1 in the groups of chronic hepatitis and cirrhosis is not significantly different (p>0.05). A relationshipwas established between the level of DEFA1 in patients with chronic liver diseases and alkaline phosphatase activity (p<0.05). In patients with chronic liver diseases, a relationship has been established between the levels of IL-13 and DEFA1 (p<0.001). ROC analysis showed that with a sensitivity of 50% and a specificity of 100% at a DEFA1 level of more than 354.8 pg / ml, it is possible to confirm the presence of diffuse liver disease (p<0.001). A relationship between the levels of IL-13, DEFA1 and next sera enzymes activities: hyaluronidase, trypsin-like, deoxyribonuclease, elastase, has been established.